Actively Recruiting
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
Led by RenJi Hospital · Updated on 2025-12-09
84
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
Sponsors
R
RenJi Hospital
Lead Sponsor
W
West China Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual disease (MRD) and early diagnosis of UTUC recurrence, and explored the role of ctDNA and utDNA detection of MRD in the prediction of adjuvant therapy efficacy and prognostic evaluation.
CONDITIONS
Official Title
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed upper tract urothelial carcinoma at stage T2-4 or with lymph node involvement (N+) and no distant metastasis (M0)
- Male or female aged 18 years or older willing to sign informed consent
- ECOG performance status between 0 and 2
- Underwent radical nephroureterectomy for upper tract urothelial carcinoma
- No history of multiple primary carcinomas
- Received adjuvant chemotherapy or immunotherapy within 12 weeks after surgery
- At least two postoperative liquid biopsy assessments (T1 and T2)
You will not qualify if you...
- Prior history of bladder cancer or concurrent bladder cancer
- Pregnant or breastfeeding women, or fertile patients not using contraception
- Severe infection
- Serious heart disease
- Uncontrolled neurological or mental disorders
- Severe diabetes mellitus
- Severe autoimmune diseases
- Exposure to neoadjuvant therapy
- No bilateral upper tract urothelial carcinoma
- Surveillance period less than one month
- Fewer than two postoperative minimal residual disease surveillance assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital
Shanghai, Shanghai Municipality, China, 200127
Actively Recruiting
Research Team
J
jiwei huang, M.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here